Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan to Revise Revlimid Risk Management Rule in June; February Generic Approval Eyed
A health ministry safety panel on January 24 approved a plan to revise the “RevMate” risk management program for Revlimid (lenalidomide), a blood cancer drug known to cause birth defects, in June, anticipating the listing of its generic versions as…
To read the full story
Related Article
- MHLW Panel OKs Different Safety Scheme for Fujimoto’s Revlimid Generic despite Concerns
June 27, 2024
- First Generics for 11 APIs to Enter NHI Price List, Azilva Faces Most Contenders
June 15, 2023
- MHLW Approves First Generics for Azilva, Revlimid towards June Listing
February 16, 2023
- No Add'l Safety Measures for Xocova Needed “at This Time”: MHLW Panel
December 28, 2022
- Japan Panel OKs Risk Management Measures for Potential Revlimid Generics
May 25, 2022
- MHLW Panel Roughly OKs Scheme for Generic Makers to Join Revlimid Risk Management Program
June 23, 2021
REGULATORY
- MHLW Issues Q&A on Conditional Approval System
May 1, 2026
- Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
May 1, 2026
- METI Clarifies Naphtha Comments, Reaffirms Medical Priority
April 30, 2026
- Japan Minister Rules Out Full Self-Pay for OTC-Like Drugs
April 30, 2026
- Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
April 30, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…